Menu Search
Equities

LILLY DRN

LILY34:SAO

LILLY DRN

Actions
  • Price (BRL)170.15
  • Today's Change4.19 / 2.52%
  • Shares traded7.81k
  • 1 Year change+83.35%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		LLY:NYQ since
announced		Transaction
value
Mablink Bioscience SASAnnounced17 Oct 202317 Oct 2023Announced49.44%--
POINT Biopharma Global IncDeal completed03 Oct 202303 Oct 2023Deal completed71.19%1.38bn
Data delayed at least 15 minutes, as of Sep 21 2024 00:00 BST.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Caixa DTVM SAas of 31 May 2024422.74k0.00%
Western Asset Management Company DTVM Ltda.as of 31 May 2024195.77k0.00%
Bram Bradesco Asset Management S/A DTVMas of 31 May 202450.61k0.00%
Safra Asset Management Ltda.as of 31 May 202430.00k0.00%
Warren Brasil Gest�o e Administra��o e Recursos Ltda.as of 31 May 20249.63k0.00%
XP Allocation Asset Management Ltda.as of 31 May 20241.43k0.00%
Santander Brasil Gest�o de Recursos Ltda.as of 31 May 20241.39k0.00%
BB Gest�o de Recursos DTVM SAas of 31 May 20241.00k0.00%
More ▼
Data from 31 May 2024 - 11 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.